Special Reports

By Maureen Martino and Liz Jones Welcome to our annual report on the top biotech venture capital deals. 2009 was an incredibly difficult year for biotech companies to raise venture funding, as the

While the much-talked-about patent cliff won't hit until 2011, 2010 will still see patent expirations of some of the industry's blockbuster drugs. Teva, Apotex, Mylan and a slew of other generic

Nile navigates its way to Phase III for AHF Nile Therapeutics is a small developer targeting a very big market. Founded five years ago, San Mateo, CA-based Nile--which is operating with only four

If there was a hot trend for 2009 biopharma buyouts, it was the mega-merger. Usually a rare animal, three of the industry's biggest players--Wyeth, Genentech and Schering-Plough--were swept off the

Fledgling Alnara plots a 2010 market launch As chief scientific officer for Altus Pharmaceuticals, Alexey Margolin, PhD, grew intimately familiar with ALTU-135, an experimental pancreatic enzyme

A venture veteran hears the call of clinical development Just before Scott Minick joined Arch Venture Partners back in 1998, he made his mark as president and COO of Sequus Pharmaceuticals, which

2009 was a rough year for companies that rely on venture capital. Rocked by turbulent changes in the industry, venture funds were less generous with funding as they battened down the hatches and

Reata lassoes some hard-won attention For a biotech with solid venture backing, some 50 employees and a significant licensing deal under its belt after reeling in convincing mid-stage data on a

Regado capitalizes on good relationships In biotechnology, good relationships are crucial to a long and fruitful career. And David Mazzo, PhD, knows that first hand. After Mazzo and the board at

Oncothyreon clears the deck for clinical trial work The past year has brought some big changes at Oncothyreon. Twelve months ago the Seattle-based developer struck a deal to sell its manufacturing